Wutah dodolan YoY sajrone 12 wulan kepungkur: Immunocore Holdings plc (IMCR)

Immunocore Holdings plc is scaling cancer immunotherapy through partnerships with pharmaceutical behemoths. The technology stack has been enhanced with synthesis automation, although final tests remain the responsibility of physicians. The current year-over-year revenue growth (TTM) confirms this trend, where the parameter equals 13.20. This trend is driven by the market launch of targeted drugs, which are currently in a phase of active commercial growth.
Immunocore (IMCR) - rincian metrik lan laporan keuangan

The scale of Immunocore Holdings plc (IMCR) expansion in the field of cancer immunotherapy and the effectiveness of its strategic alliances are reflected in the TTM revenue growth. This metric measures the percentage change in total sales over the last 12 months relative to the previous year, representing the market consensus on the business's ability to scale the commercialization of the ImmTAX platform and strengthen its fundamental resilience.